Table 3 In 51 ANAS patients with CSF, factors associated with outcomes or relapses in univariate analysis
From: Anti-neuron antibody syndrome: clinical features, cytokines/chemokines and predictors
Outcomes | Relapses | ||||||
|---|---|---|---|---|---|---|---|
Good outcomes | Poor outcomes | p | No relapse | Relapses | p | ||
Elevated CSF PRO | 0.0123 | Elevated CSF PRO | 0.0632 | ||||
No | 29(76.32) | 4(33.33) | No | 17(54.84) | 16(84.21) | ||
Yes | 9(23.68) | 8(66.67) | Yes | 14(45.16) | 3(15.79) | ||
AE or PNS | 0.0372 | AE or PNS | 0.0737 | ||||
AE | 28(71.79) | 4(33.33) | AE | 16(51.61) | 16(80.00) | ||
PNS | 11(28.21) | 8(66.67) | PNS | 15(48.39) | 4(20.00) | ||
Tumours | <0.0001 | CSF IL10 | 14.99(1.48-80.63) | 7.8(1.02-28.29) | 0.0913 | ||
No | 36(92.31) | 4(33.33) | |||||
Yes | 3(7.69) | 8(66.67) | |||||
Types of onset | 0.001 | Serum TGFβ1 | 52379.98(15370.86-113337.9) | 69013.08(27451.21-118364.7) | 0.0202 | ||
Acute | 32(82.05) | 4(33.33) | |||||
Sub-acute | 2(5.13) | 1(8.33) | |||||
Chronic | 5(12.82) | 7(58.33) | |||||
CSF BAFF | 267.68(2.54-3064.00) | 742.31(89.23-2670.00) | 0.0606 | CSF BAFF | 370.9(2.54-3064.00) | 242.77(36.56-1367.00) | 0.099 |
Serum TGFβ1/CSF CXCL10 | 102.48(7.33-927.55) | 310.13(6.02-3235.45) | 0.0048 | ||||
Serum TGFβ1/serum CXCL13 | 574.07(70.48,2913.36) | 1041.71(264.89,1618.54) | 0.0455 | ||||
Serum TGFβ1/serum BAFF | 41.76(5.34-113.62) | 64.24(21.85-140.59) | 0.0279 | ||||
CSF TGFβ1/serum TGFβ1 | 0.00064(0.00012-0.049) | 0.00025(0.00014-0.0016) | 0.0205 | ||||
Serum TGFβ1/CSF BAFF | 114.29(16.12-1043.37) | 359.88(55.28-2646.06) | 0.0076 | ||||